Transformation of Chronic Myeloid Leukemia to Acute Undifferentiated Leukemia: Case Report and Literature Review

Abstract: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm driven by the BCR::ABL1 fusion gene and typically progresses through chronic, accelerated, and blast crisis phases. While blast crises often present with myeloid or lymphoid phenotypes, transformation to acute undifferentiated leukemia (AUL) is exceedingly rare and presents significant diagnostic and therapeutic challenges. We describe a 41-year-old female with CML whose disease transformed to AUL during blast crisis. Initially treated with imatinib, therapy was discontinued due to loss of response, followed by a brief, intolerant course of nilotinib. After 2 years without treatment, she presented with general deterioration, anemia, and splenomegaly. Laboratory findings revealed hyperleukocytosis, severe thrombocytopenia, and 27% undifferentiated blasts on peripheral blood smear; bone marrow aspiration confirmed 53% blasts with negative myeloperoxidase staining. Immunophenotyping confirmed AUL, showing blasts with weak CD45 expression, CD34 positivity, HLA-DR positivity, and absence of lineage-specific markers, whereas cytogenetic analysis revealed a complex karyotype. The patient was treated with a 3 + 7 chemotherapy regimen but developed infectious complications, ultimately succumbing to cardiovascular arrest. This case highlights the complexity and poor prognosis of atypical CML transformations. It underscores the need for a deeper understanding of blast crisis mechanisms and innovative therapeutic strategies to improve patient care and outcomes.

Authors

Institutions

Publication Details

Journal
Journal of Applied Hematology
Published
2025-04-01
DOI
https://doi.org/10.4103/joah.joah_53_25
Citations
1
Primary Topic
Chronic Myeloid Leukemia Treatments
Type
article
Field-Weighted Citation Impact
1.77
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Transformation of Chronic Myeloid Leukemia to Acute Undifferentiated Leukemia: Case Report and Literature Review

Rachid Seddik, M. Bensalah, Nabiha Trougouty, Abdelilah Berhili et al.
1 citations
Journal of Applied Hematology
Chronic Myeloid Leukemia Treatments
1.77
article

Transformation of Chronic Myeloid Leukemia to Acute Undifferentiated Leukemia: Case Report and Literature Review

Rachid Seddik, M. Bensalah, Nabiha Trougouty, Abdelilah Berhili, Mounia Slaoui, Nisma Douzi, Oussama Grari, Amina Himri, Assya Khermach, Nouhaila Chahid
article en
1 citations

Abstract

Abstract: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm driven by the BCR::ABL1 fusion gene and typically progresses through chronic, accelerated, and blast crisis phases. While blast crises often present with myeloid or lymphoid phenotypes, transformation to acute undifferentiated leukemia (AUL) is exceedingly rare and presents significant diagnostic and therapeutic challenges. We describe a 41-year-old female with CML whose disease transformed to AUL during blast crisis. Initially treated with imatinib, therapy was discontinued due to loss of response, followed by a brief, intolerant course of nilotinib. After 2 years without treatment, she presented with general deterioration, anemia, and splenomegaly. Laboratory findings revealed hyperleukocytosis, severe thrombocytopenia, and 27% undifferentiated blasts on peripheral blood smear; bone marrow aspiration confirmed 53% blasts with negative myeloperoxidase staining. Immunophenotyping confirmed AUL, showing blasts with weak CD45 expression, CD34 positivity, HLA-DR positivity, and absence of lineage-specific markers, whereas cytogenetic analysis revealed a complex karyotype. The patient was treated with a 3 + 7 chemotherapy regimen but developed infectious complications, ultimately succumbing to cardiovascular arrest. This case highlights the complexity and poor prognosis of atypical CML transformations. It underscores the need for a deeper understanding of blast crisis mechanisms and innovative therapeutic strategies to improve patient care and outcomes.

Journal of Applied HematologyVol. 16(2)
Mohamed I University (MA)
Openalex Percentile: Top 15%
Chronic Myeloid Leukemia Treatments
1.77
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.